Bottom line
MRAGX vs FDGRX: the short answer
MRAGX (Meridian Growth Fund) and FDGRX (Fidelity Growth Company Fund) are both mutual funds.
But FDGRX is far broader, holding 649 positions to 91 for MRAGX, so beyond the top names it adds exposure MRAGX doesn't have.
FDGRX is cheaper at 0.69% vs 1.29% — a difference of $60 a year per $10,000 invested.
Over five years, FDGRX returned +15.3% a year vs −2.7% for MRAGX (reporting dates differ).
MRAGX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
MRAGX vs FDGRX side by side
| MRAGX | FDGRX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Meridian | Fidelity |
| Category | Large Growth | Large Growth |
| Expense ratio | 1.29% | 0.69% |
| Annual cost per $10k | $129 | $69 |
| 10-yr cost on $10k (prospectus) | $2,042 | $859 |
| Max front load | 5.75% | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −11.9% | +24.3% |
| 5-yr return (annualized) | −2.7% | +15.3% |
| 10-yr return (annualized) | +6.4% | +20.7% |
| Best quarter | — | +40.6% |
| Worst quarter | — | −25.0% |
| Net assets (fund) | $542.9M | $98.8B |
| Number of holdings | 91 | 649 |
| Portfolio turnover | 49% | 16% |
| Returns as of | Dec 31, 2025 | Jan 31, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MRAGX and FDGRX share none of their top holdings.
MRAGX top 10
- Stit Govt And Agency Inst — 4.17%
- Rb Global Inc — 2.49%
- Curtiss-wright Corp — 2.46%
- Axogen Inc — 2.43%
- Federal Signal Corp — 2.36%
- Hinge Health Inc — 2.29%
- Definium Therapeutics Inc — 2.20%
- Veracyte Inc — 2.14%
- Standardaero Inc — 2.09%
- Turning Point Brands Inc — 2.08%
FDGRX top 10
- Nvidia Corp — 15.76%
- Apple Inc — 7.56%
- Microsoft Corp — 5.94%
- Amazon.com Inc — 5.30%
- Alphabet Inc — 4.43%
- Sandisk Corp/de — 3.89%
- Ciena Corp — 3.76%
- Alphabet Inc — 3.12%
- Meta Platforms Inc — 2.82%
- Broadcom Inc — 2.29%
FAQ
What is the difference between MRAGX and FDGRX?
Which is cheaper, MRAGX or FDGRX?
Should I own both MRAGX and FDGRX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.